Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus-Reference-Cited by-同舟云学术

Exploring the antiviral activities of the FDA-approved drug sulfadoxine and its derivatives against Chikungunya virus

Published:2024-08-16 Issue:5 Volume:76 Page:1147-1159
ISSN:1734-1140
Container-title:Pharmacological Reports
language:en
Short-container-title:Pharmacol. Rep

Author:

Martins Daniel Oliveira Silva,Ruiz Uriel Enrique Aquino,Santos Igor Andrade,Oliveira Igor Santos,Guevara-Vega Marco,de Paiva Raphael Enoque Ferraz,Abbehausen Camilla,Sabino-Silva Robinson,Corbi Pedro Paulo,Jardim Ana Carolina Gomes^ORCID

Funder

Fundação de Amparo à Pesquisa do Estado de Minas Gerais

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Fundação de Amparo à Pesquisa do Estado de São Paulo

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s43440-024-00635-z.pdf

Reference46 articles.

1. Gould E, Pettersson J, Higgs S, Charrel R, de Lamballerie X. Emerging arboviruses: why today? One Health. 2017;4:1–13. https://doi.org/10.1016/j.onehlt.2017.06.001

2. Kraemer MUG, Sinka ME, Duda KA, Mylne AQN, Shearer FM, Barker CM, et al. The global distribution of the arbovirus vectors aedes aegypti and ae. Albopictus Elife. 2015;4:1–18. https://doi.org/10.7554/eLife.08347

3. Yactayo S, Staples JE, Millot V, Cibrelus L, Ramon-Pardo P. Epidemiology of Chikungunya in the Americas. J Infect Dis. 2016;214:S441–5. https://doi.org/10.1093/infdis/jiw390

4. Weaver SC, Charlier C, Vasilakis N, Lecuit M. Zika, Chikungunya, and other emerging vector-borne viral diseases. Annu Rev Med. 2018;69. https://doi.org/10.1146/annurev-med-050715-105122

5. Schwartz O, Albert ML. Biology and pathogenesis of Chikungunya virus. Nat Rev Microbiol. 2010;8:491–500. https://doi.org/10.1038/nrmicro2368